HUTCHMED (HCM) Competitors

HUTCHMED logo
GBX 217 -6.00 (-2.69%)
As of 12:42 PM Eastern

HCM vs. DPH, HIK, INDV, VEC, and SER

Should you buy HUTCHMED stock or one of its competitors? HUTCHMED's main competitors and comparable companies include Dechra Pharmaceuticals (DPH), Hikma Pharmaceuticals (HIK), Indivior (INDV), Vectura Group (VEC), and 5533861 (SER.L) (SER). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does HUTCHMED compare to Dechra Pharmaceuticals?

HUTCHMED (LON:HCM) and Dechra Pharmaceuticals (LON:DPH) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

HUTCHMED has a net margin of 163.84% compared to Dechra Pharmaceuticals' net margin of -3.66%. HUTCHMED's return on equity of 18.42% beat Dechra Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMED163.84% 18.42% -5.90%
Dechra Pharmaceuticals -3.66%-3.92%0.75%

20.7% of HUTCHMED shares are held by institutional investors. Comparatively, 105.5% of Dechra Pharmaceuticals shares are held by institutional investors. 2.8% of HUTCHMED shares are held by insiders. Comparatively, 9.3% of Dechra Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Dechra Pharmaceuticals has higher revenue and earnings than HUTCHMED. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED£549.12M3.43-£52.98M£2.00108.50
Dechra Pharmaceuticals£761.50M0.00-£27.90M-£0.25N/A

In the previous week, HUTCHMED had 2 more articles in the media than Dechra Pharmaceuticals. MarketBeat recorded 2 mentions for HUTCHMED and 0 mentions for Dechra Pharmaceuticals. HUTCHMED's average media sentiment score of 0.26 beat Dechra Pharmaceuticals' score of 0.00 indicating that HUTCHMED is being referred to more favorably in the media.

Company Overall Sentiment
HUTCHMED Neutral
Dechra Pharmaceuticals Neutral

HUTCHMED has a beta of 0.428, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Dechra Pharmaceuticals has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Summary

HUTCHMED and Dechra Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does HUTCHMED compare to Hikma Pharmaceuticals?

HUTCHMED (LON:HCM) and Hikma Pharmaceuticals (LON:HIK) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Hikma Pharmaceuticals has a consensus target price of GBX 1,986.25, suggesting a potential upside of 18.09%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HUTCHMED
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Hikma Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

20.7% of HUTCHMED shares are held by institutional investors. Comparatively, 63.6% of Hikma Pharmaceuticals shares are held by institutional investors. 2.8% of HUTCHMED shares are held by insiders. Comparatively, 22.3% of Hikma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

HUTCHMED has a beta of 0.428, indicating that its share price is 57% less volatile than the broader market. Comparatively, Hikma Pharmaceuticals has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

In the previous week, Hikma Pharmaceuticals had 3 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Hikma Pharmaceuticals and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.26 beat Hikma Pharmaceuticals' score of -0.06 indicating that HUTCHMED is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
HUTCHMED
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Hikma Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

HUTCHMED has a net margin of 163.84% compared to Hikma Pharmaceuticals' net margin of 11.31%. HUTCHMED's return on equity of 18.42% beat Hikma Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMED163.84% 18.42% -5.90%
Hikma Pharmaceuticals 11.31%15.05%9.40%

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED£549.12M3.43-£52.98M£2.00108.50
Hikma Pharmaceuticals£3.42B1.02£353.21M£176.009.56

Summary

Hikma Pharmaceuticals beats HUTCHMED on 11 of the 16 factors compared between the two stocks.

How does HUTCHMED compare to Indivior?

HUTCHMED (LON:HCM) and Indivior (LON:INDV) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

HUTCHMED has a net margin of 163.84% compared to Indivior's net margin of 0.17%. HUTCHMED's return on equity of 18.42% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMED163.84% 18.42% -5.90%
Indivior 0.17%-1.11%2.37%

Indivior has higher revenue and earnings than HUTCHMED. Indivior is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED£549.12M3.43-£52.98M£2.00108.50
Indivior£1.40B1.38-£2.36M-£1.21N/A

HUTCHMED has a beta of 0.428, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Indivior has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

20.7% of HUTCHMED shares are owned by institutional investors. Comparatively, 86.0% of Indivior shares are owned by institutional investors. 2.8% of HUTCHMED shares are owned by company insiders. Comparatively, 3.4% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, HUTCHMED had 2 more articles in the media than Indivior. MarketBeat recorded 2 mentions for HUTCHMED and 0 mentions for Indivior. HUTCHMED's average media sentiment score of 0.26 beat Indivior's score of 0.00 indicating that HUTCHMED is being referred to more favorably in the media.

Company Overall Sentiment
HUTCHMED Neutral
Indivior Neutral

Summary

HUTCHMED beats Indivior on 8 of the 13 factors compared between the two stocks.

How does HUTCHMED compare to Vectura Group?

HUTCHMED (LON:HCM) and Vectura Group (LON:VEC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, HUTCHMED had 2 more articles in the media than Vectura Group. MarketBeat recorded 2 mentions for HUTCHMED and 0 mentions for Vectura Group. HUTCHMED's average media sentiment score of 0.26 beat Vectura Group's score of 0.00 indicating that HUTCHMED is being referred to more favorably in the media.

Company Overall Sentiment
HUTCHMED Neutral
Vectura Group Neutral

HUTCHMED has a net margin of 163.84% compared to Vectura Group's net margin of 0.00%. HUTCHMED's return on equity of 18.42% beat Vectura Group's return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMED163.84% 18.42% -5.90%
Vectura Group N/A N/A N/A

20.7% of HUTCHMED shares are held by institutional investors. 2.8% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Vectura Group has lower revenue, but higher earnings than HUTCHMED. Vectura Group is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED£549.12M3.43-£52.98M£2.00108.50
Vectura Group£190.60M0.00N/A£20.10N/A

Summary

HUTCHMED beats Vectura Group on 8 of the 10 factors compared between the two stocks.

How does HUTCHMED compare to 5533861 (SER.L)?

HUTCHMED (LON:HCM) and 5533861 (SER.L) (LON:SER) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

In the previous week, HUTCHMED had 2 more articles in the media than 5533861 (SER.L). MarketBeat recorded 2 mentions for HUTCHMED and 0 mentions for 5533861 (SER.L). HUTCHMED's average media sentiment score of 0.26 beat 5533861 (SER.L)'s score of 0.00 indicating that HUTCHMED is being referred to more favorably in the media.

Company Overall Sentiment
HUTCHMED Neutral
5533861 (SER.L) Neutral

5533861 (SER.L) has a consensus target price of GBX 320, suggesting a potential upside of 40.97%. Given 5533861 (SER.L)'s stronger consensus rating and higher probable upside, analysts clearly believe 5533861 (SER.L) is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HUTCHMED
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
5533861 (SER.L)
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

HUTCHMED has a net margin of 163.84% compared to 5533861 (SER.L)'s net margin of 0.00%. HUTCHMED's return on equity of 18.42% beat 5533861 (SER.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMED163.84% 18.42% -5.90%
5533861 (SER.L) N/A N/A N/A

5533861 (SER.L) has higher revenue and earnings than HUTCHMED.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED£549.12M3.43-£52.98M£2.00108.50
5533861 (SER.L)£973.63M0.91N/AN/AN/A

20.7% of HUTCHMED shares are held by institutional investors. Comparatively, 26.6% of 5533861 (SER.L) shares are held by institutional investors. 2.8% of HUTCHMED shares are held by company insiders. Comparatively, 14.3% of 5533861 (SER.L) shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

5533861 (SER.L) beats HUTCHMED on 7 of the 12 factors compared between the two stocks.

Get HUTCHMED News Delivered to You Automatically

Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HCM vs. The Competition

MetricHUTCHMEDPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£1.89B£13.61B£7.74B£2.79B
Dividend Yield4.63%2.58%2.46%5.11%
P/E Ratio108.5029.4134.1723.17
Price / Sales3.437.028.485.10
Price / Cash2.4915.7421.9320.23
Price / Book2.485.114.372.48
Net Income-£52.98M£2.88B£3.52B£5.88B
7 Day Performance-4.41%-4.11%-5.47%-1.22%
1 Month Performance0.46%-5.09%-4.58%-2.86%
1 Year Performance-5.65%-7.45%-1.79%6.43%

HUTCHMED Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HCM
HUTCHMED
N/AGBX 217
-2.7%
N/A-2.2%£1.89B£549.12M108.501,760
DPH
Dechra Pharmaceuticals
N/AN/AN/AN/A£4.40B£761.50MN/A2,457
HIK
Hikma Pharmaceuticals
3.203 of 5 stars
GBX 1,650
-2.8%
GBX 1,998.75
+21.1%
+5.8%£3.65B£3.42B9.389,500
INDV
Indivior
N/AGBX 1,238
+1.6%
N/A+0.0%£1.93B£1.40BN/A1,000
VEC
Vectura Group
N/AN/AN/AN/A£1.01B£190.60M8.209,200

Related Companies and Tools


This page (LON:HCM) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners